Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

Inclusion Criteria:

• Participants voluntarily participate in the study, and sign the Informed ConsentForm (ICF) prior to screening, able to complete the study according to the protocol;

• Male or female participants aged 18-65 years old (including the boundary value) atthe time of signing the ICF;

• Male participants weighed higher than 50 kg and female participants weighted higherthan 50 kg, Body Mass Index (BMI) between 18 to 32 kg/m^2(inclusive);

• Participants with positive HBsAg or HBV DNA greater than or equal to (≥) 6 monthsprior to screening and has not received antiviral treatment with interferon or NAs ;

• At screening, ALT<3×upper limit of normal (ULN);

• Use effective contraception as required;

• HBV DNA within the specified range at screening;

• HBsAg was within the specified range at screening.

Exclusion Criteria:

• Clinically significant abnormalities except chronic HBV infection;

• Any clinically significant liver diseases;

• Participants with severe infection requiring systemic anti-infection treatment 1month before enrollment;

• Active hepatitis C, HIV antibody positive, treponema pallidum antibody positive;

• Hepatobiliary neoplasm malignant;

• The laboratory examination results are obviously abnormal;

• History of vasculitis or signs and symptoms of potential vasculitis;

• Anti-neutrophil cytoplasmic antibodies (ANCA) was positive at screening.

• History of extrahepatic disease that may be related to HBV immune status;

• Administration of immunosuppressants within 3 months prior to screening, except forshort-term use (≤2 weeks) or topical/inhaled steroids. Administration ofimmunomodulators (thymosin) and cytotoxic drugs within 6 months prior to the firststudy intervention or have a history of vaccination within 1 month prior toscreening or planned administration during the study;

• History of malignancy within the past 5 years or the discovery of suspected tumorsduring the screening period;

• Any suspicion of drug component allergy, or allergic constitution (various drug andfood allergy, and judged by the investigator to be clinically significant) inparticipants;

• Participants who have significant trauma or major surgery within 3 months beforescreening, or plan to perform surgery during the study;

• Blood donation or blood loss more than 400 mL within 12 weeks before screening;Blood transfusion; Blood donation or blood loss not less than 200 mL within 1 monthbefore screening;

• Those who are participating in another clinical trial, or have not undergone aprotocol-specified washout period prior to this study;

• Participants who have received any oligonucleotide or small molecule interferingribonucleic acid (siRNA) drugs;

• Any other circumstances or conditions for which the investigator considers that theparticipants are inappropriate to participate in the study.